<DOC>
	<DOCNO>NCT01303328</DOCNO>
	<brief_summary>The purpose phase-II study evaluate efficacy safety aqueous gel contain antiviral , administer directly cervix exhibit high grade squamous glandular intraepithelial lesion ( CIN 2 3 ) comparison placebo treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Antiviral Local Application Treat High Grade Cervical Intraepithelial Lesions ( CIN2/3 )</brief_title>
	<detailed_description>Human Papilloma Virus ( HPV ) infection induce cervical intraepithelial neoplasia ( CIN ) cervix . To reduce incidence invasive tumor associate high grade CIN lesion , standard treatment conisation cervix ( surgical act ) . A local treatment antiviral would preserve cervix young subject reduce obstetrical morbidity induce conisation . This clinical study aim : - evaluate efficacy gel antiviral directly apply cervix exhibit high grade CIN lesion ( CIN2/3 ) : conisation still indicate ? - evaluate safety tolerance local application .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Women age 18 50 year old Informed consent sign Cervical lesion classify CIN 2 3 , biopsy make 60 day inclusion No sexual activity , prove sterility , use effective mechanical , hormonal intrauterine contraception 30 day follow inclusion ( except vaginal ring Nuvaring , diaphragm spermicide ) Invasive microinvasive cervical neoplasia Pregnancy breast feed Subtotal hysterectomy Current renal impairment Current immune disorder include serology HIV + Current use drug interfere renal function Current use oncologic treatment Current use immune treatment Current use antiviral treatment Current vaginal application drug cosmetic Prior treatment antiviral cervix Local general condition incompatible experimental treatment opinion principal investigator Current recent participation another experimental study last 3 month screen visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>